Security
Aprea Therapeutics, Inc. Common stock · APRE
APRENASDAQCommon stockCurrentCIK 1781983Updated Oct 6, 2026
APRE price & chart
Loading TradingView…
NASDAQ:APRE on TradingView ↗About the company
Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast cancers. The company’s lead programs are
In the news
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology ↗
Recent filings
Other Events
Items 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 14,321,316Source | 26,893,969Source | 42,289,924Source | 17,309,710Source | 29,964,587Source | 47,612,387Source | 20,222,083Source | 33,200,006Source | 15,933,401Source | 23,979,493Source | 22,650,174Source | 30,155,827Source |
| Property, Plant and Equipment, NetUSD | 65,236Source | 86,950Source | 64,033Source | 70,665Source | 92,379Source | 54,379Source | 76,093Source | 90,183Source | 59,807Source | 81,522Source | 88,362Source | 2,321Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 13,718,052Source | 26,249,625Source | 41,233,428Source | 16,532,199Source | 28,694,694Source | 46,466,202Source | 19,275,721Source | 32,369,973Source | 14,599,347Source | 22,849,885Source | 21,606,820Source | 28,786,647Source |
| Assets, CurrentUSD | 13,943,988Source | 26,483,820Source | 41,913,114Source | 16,927,210Source | 29,559,786Source | 47,245,440Source | 19,834,410Source | 33,068,837Source | 15,561,246Source | 23,576,139Source | 22,521,095Source | 30,153,506Source |
| Prepaid Expense and Other Assets, CurrentUSD | 225,936Source | 234,195Source | 679,686Source | 395,011Source | 865,092Source | 779,238Source | 558,689Source | 698,864Source | 961,899Source | 726,254Source | 914,275Source | 1,366,859Source |
| Other Assets, NoncurrentUSD | 271,162Source | 281,662Source | 271,162Source | 271,162Source | 271,162Source | 271,162Source | 271,162Source | — | 271,162Source | 281,662Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 3,201,086Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 5,979Source | 5,435Source | 12,391Source | 5,752Source | 5,430Source | 11,983Source | 5,513Source | 5,430Source | 8,192Source | 5,481Source | 3,736Source | 2,655Source |
| Additional Paid in CapitalUSD | 352,722,214Source | 350,693,403Source | 389,596,149Source | 352,250,747Source | 350,545,473Source | 389,631,454Source | 351,145,676Source | 350,438,045Source | 356,709,645Source | 350,971,225Source | 335,644,204Source | 330,060,836Source |
| Retained Earnings (Accumulated Deficit)USD | -331,185,811Source | -318,147,073Source | -340,520,662Source | -328,213,401Source | -314,363,304Source | -336,929,358Source | -324,974,531Source | -310,893,252Source | -333,641,441Source | -321,041,872Source | -308,083,161Source | -293,796,405Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -10,629,534Source | -10,604,747Source | -10,617,617Source | -10,628,417Source | -10,628,304Source | -10,625,700Source | -10,626,736Source | -10,626,356Source | -10,634,714Source | -10,627,379Source | -10,611,273Source | -10,623,408Source |
| Stockholders' Equity Attributable to ParentUSD | 10,912,848Source | 21,947,018Source | 38,470,261Source | 13,414,681Source | 25,559,295Source | 41,588,380Source | 15,549,922Source | 28,923,867Source | 12,441,682Source | 19,307,455Source | 16,953,506Source | 25,643,678Source |
| Liabilities and EquityUSD | 14,321,316Source | 26,893,969Source | 42,289,924Source | 17,309,710Source | 29,964,587Source | 47,612,387Source | 20,222,083Source | 33,200,006Source | 15,933,401Source | 23,979,493Source | 22,650,174Source | 30,155,827Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,681,107Source | 3,635,888Source | 3,092,302Source | 3,167,668Source | 3,094,229Source | 5,296,646Source | 3,361,098Source | 2,965,076Source | 2,764,358Source | 3,360,975Source | 4,385,605Source | 3,201,086Source |
| Accounts Payable, CurrentUSD | 641,322Source | 1,153,880Source | 935,139Source | 1,195,838Source | 964,327Source | 2,940,756Source | 1,281,651Source | 1,318,385Source | 713,668Source | 1,352,240Source | 1,670,369Source | 842,754Source |
| Additional Financial Items | ||||||||||||
| Deferred Revenue, CurrentUSD | — | — | — | — | 50,739Source | — | — | 148,405Source | — | — | 528,974Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -3,287,917Source | -3,932,659Source | -12,599,569Source | -12,958,711Source | -14,286,756Source | -112,662,027Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 5,428Source | 5,429Source | 21,715Source | 22,318Source | 7,052Source | 4,403Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 32,525Source | -71,935Source | -646,701Source | -314,207Source | 827,463Source | -858,513Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,756,726Source | -3,631,163Source | -12,894,439Source | -13,556,718Source | -12,177,608Source | -25,011,136Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | -15,478Source | -93,093Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 15,478Source | 93,093Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 34,624,149Source | 55,849Source | 4,640,238Source | 14,821,895Source | 5,139,990Source | 682,973Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 13,758,982Source | 26,291,162Source | 41,275,043Source | 16,572,872Source | 46,507,608Source | 19,316,139Source | 14,640,533Source | 22,890,055Source | 21,647,537Source | 28,786,647Source |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -5,691Source | -35,494Source | 2,953Source | -29,124Source | 7,711Source | -51,803Source | -95,319Source | 71,800Source | -38,926Source | 281,534Source |
| General and Administrative ExpenseUSD | — | — | 1,480,319Source | 1,605,238Source | 1,570,138Source | 1,593,671Source | 1,819,245Source | 1,764,979Source | 6,476,560Source | 6,458,699Source | 8,427,703Source | 20,969,771Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,972,410Source | -3,783,769Source | -3,591,304Source | -3,238,870Source | -3,287,917Source | -3,932,659Source | -12,599,569Source | -12,958,711Source | -14,286,756Source | -112,662,027Source |
| Operating ExpensesUSD | — | — | 3,119,236Source | 4,451,637Source | 4,032,180Source | 3,505,884Source | 3,430,412Source | 4,248,045Source | 13,519,595Source | 15,822,236Source | 16,055,194Source | 113,392,228Source |
| Other Nonoperating Income (Expense)USD | — | — | 144,978Source | 313,247Source | 440,876Source | 148,903Source | 142,495Source | 152,923Source | 634,267Source | 1,360,944Source | 1,185,207Source | 730,201Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 35,098,813Source | 59,234Source | 5,047,606Source | 16,140,356Source | 5,788,918Source | 682,973Source |
| Share-based Payment Arrangement, Expense | — | — | —Source | — | —Source | —Source | — | —Source | — | — | — | — |
| Operating Lease, Expense | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -3,117,388Source | -4,097,016Source | -4,032,180Source | -3,387,773Source | -3,430,412Source | -4,085,582Source | -13,233,836Source | -14,319,655Source | -15,471,963Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 144,978Source | 313,247Source | 440,876Source | 148,903Source | 142,495Source | 152,923Source | 634,267Source | 1,360,944Source | 1,185,207Source | 730,201Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,972,410Source | -3,783,769Source | -3,591,304Source | -3,238,870Source | -3,287,917Source | -3,932,659Source | -12,599,569Source | -12,958,711Source | -14,286,756Source | -112,662,027Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.47Source | -0.64Source | -0.07Source | -0.53Source | -0.22Source | -0.66Source | -1.93Source | -2.35Source | -3.95Source | -67.99Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.47Source | -0.64Source | -0.07Source | -0.53Source | -0.22Source | -0.66Source | -1.93Source | -2.45Source | -3.95Source | -68.16Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 6,372,938Source | 5,939,755Source | 53,483,504Source | 6,083,329Source | 14,685,448Source | 5,993,866Source | 6,538,722Source | 5,509,921Source | 3,617,607Source | 1,657,055Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 6,372,938Source | 5,939,755Source | 53,483,504Source | 6,083,329Source | 14,685,448Source | 5,993,866Source | 6,538,722Source | 5,509,921Source | 3,617,607Source | 1,657,055Source |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -5,691Source | -35,494Source | 2,953Source | -29,124Source | 7,711Source | -51,803Source | -95,319Source | 71,800Source | -38,926Source | 281,534Source |
| General and Administrative ExpenseUSD | — | — | 1,480,319Source | 1,605,238Source | 1,570,138Source | 1,593,671Source | 1,819,245Source | 1,764,979Source | 6,476,560Source | 6,458,699Source | 8,427,703Source | 20,969,771Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 150,669Source | 348,741Source | 358,923Source | 178,027Source | 134,784Source | 204,726Source | 652,086Source | 1,289,144Source | 1,224,133Source | 448,667Source |
| Operating ExpensesUSD | — | — | 3,119,236Source | 4,451,637Source | 4,032,180Source | 3,505,884Source | 3,430,412Source | 4,248,045Source | 13,519,595Source | 15,822,236Source | 16,055,194Source | 113,392,228Source |
| Operating Lease, Expense | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-295247
Registration 333-293609
Filing attachments
apre-20260828xex99d1.htm · 8-K · 2026-08-28
EX-99.1 2 apre-20260828xex99d1.htm EX-99.1 Exhibit 99.1 Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents DOYLESTOWN, PA, August 28, 2026 (GLOBE NEWSWIRE) - Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapie…
Read attachment ↗apre-20260812xex99d1.htm · 8-K · 2026-08-12
EX-99.1 2 apre-20260812xex99d1.htm EX-99.1 Exhibit 99.1 Aprea Therapeutics Announces Second Quarter 2026 Financial Results Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea plans to advance APR-1051 in uterine serous carcinoma (USC), and Cyclin E - overexpressing platinum-resistant ovarian cancer (PROC) while also evaluating combination regimens with standard of care in HPV-positive head an…
Read attachment ↗apre-20260812xex99d2.htm · 8-K · 2026-08-12
EX-99.2 3 apre-20260812xex99d2.htm EX-99.2 Exhibit 99.2 1 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved A clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers August 2026 ───────────────────────────────────────────────────────── 2 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this pres…
Read attachment ↗apre-20260513xex99d1.htm · 8-K · 2026-05-13
EX-99.1 2 apre-20260513xex99d1.htm EX-99.1 Exhibit 99.1 Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051 Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose escalation ACESOT-1051 trial of WEE1 inhibitor APR-1051 Additional clinical data from ACESOT-1051 to be provided at …
Read attachment ↗apre-20260513xex99d2.htm · 8-K · 2026-05-13
EX-99.2 3 apre-20260513xex99d2.htm EX-99.2 Exhibit 99.2 1 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved A clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers May 2026 ───────────────────────────────────────────────────────── 2 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this present…
Read attachment ↗ea028467501ex99-1.htm · SCHEDULE 13G · 2026-04-01
Exhibit 99.1 EXHIBIT A Joint Filing Agreement Soleus Private Equity GP III, LLC, a Delaware limited liability company, Soleus Private Equity Fund III, L.P., a Delaware limited partnership, Soleus PE GP III, LLC, a Delaware limited liability company, Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, Soleus Capital Management, L.P., a Delawar…
Read attachment ↗